- Within weeks of Remdesivir trial data publishing, GiLead signed a EU manufacturing deal and got the drug approved by FDA.
- The dubious circumstances of the first FDA approved covid drug shows how the company exploited and gained advantage.
- Breaches and badmouthing of WHO’s solidarity trial is a noted problem
- Added to this the lack of inclusion of critical study evidences and the absence of any outer panel expert debate for approval makes the matter dubious.
October was a good month for Gilead...
https://mfame.guru/the-dubious-case-of-remdesivir-the-first-fda-approved-covid-drug/